Intravenous infusion of enprofylline with an exponentially decreasing drug concentration in acute asthma

Ther Drug Monit. 1989;11(3):249-52. doi: 10.1097/00007691-198905000-00006.

Abstract

Nine patients (3 women), aged 29-78 years, with acute asthma were treated with the antiasthma xanthine, enprofylline, in an open-design study without a reference drug. Enprofylline was administered intravenously (i.v.) over 2 h with an exponentially decreasing concentration. This alternative infusion system was found to be simple to handle. All patients but one reached a therapeutic plasma concentration of enprofylline within 20 min, but with a lower peak plasma, concentration as compared to what previously has been found with a conventional i.v. injection of the same amount of drug. The plasma concentration of enprofylline remained on a stable and therapeutic level over the 2-h observation period. The effect on lung function was comparable to that found in other controlled trials with enprofylline. A system for i.v. administration of drugs with an exponentially decreasing concentration as an alternative to manually given i.v. injections should be further evaluated.

MeSH terms

  • Adult
  • Aged
  • Asthma / drug therapy*
  • Asthma / physiopathology
  • Blood Pressure / drug effects
  • Body Weight / drug effects
  • Bronchodilator Agents / administration & dosage
  • Bronchodilator Agents / pharmacokinetics
  • Bronchodilator Agents / therapeutic use*
  • Female
  • Heart Rate / drug effects
  • Humans
  • Injections, Intravenous
  • Middle Aged
  • Peak Expiratory Flow Rate
  • Respiratory Function Tests
  • Xanthines / administration & dosage
  • Xanthines / pharmacokinetics
  • Xanthines / therapeutic use*

Substances

  • Bronchodilator Agents
  • Xanthines
  • enprofylline